‘Fragment’ compounds are characterised by their low molecular weight (classically, Mw < 300 Da), resulting in low complexity. Therefore, hit fragments bind to their target with weak affinity compared to ‘small molecule’ hits (Mw < 500 Da). However, the modest molecular size of fragments enhances their ability to access an optimal spatial orientation relative to binding features at the target. This presents a simpler starting point for drug design compared to larger, higher affinity hits, whose greater complexity may hinder the formation of optimally directed interactions towards each molecular recognition element at the target. These fragment hits are then grown or merged or linked with other hits in a process known as fragment optimisation. A second advantage of using fragments to provide a starting point is that the same number of compounds can be used to cover a greater chemical space compared to larger molecules. This increases the chance of including molecular frameworks within a screening library that complement the target binding site in an optimal manner.